Differences between serum polar lipid profiles of male and female rheumatoid arthritis patients in response to glucocorticoid treatment

[1]  J. J. Peeters,et al.  Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis , 2016, PloS one.

[2]  G. Kitas,et al.  Cardiovascular comorbidity in rheumatic diseases , 2015, Nature Reviews Rheumatology.

[3]  Catherine M. McGrath,et al.  Lipid and Metabolic Changes in Rheumatoid Arthritis , 2015, Current Rheumatology Reports.

[4]  C. Buckley,et al.  New pathogenic insights into rheumatoid arthritis , 2015, Current opinion in rheumatology.

[5]  S. Azar,et al.  A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role , 2014, Therapeutic advances in endocrinology and metabolism.

[6]  A. Escalante,et al.  Glucocorticoid Dose Thresholds Associated With All‐Cause and Cardiovascular Mortality in Rheumatoid Arthritis , 2014, Arthritis & rheumatology.

[7]  G. Rossi,et al.  The Role of Oxidized Low-Density Lipoproteins in Atherosclerosis: The Myths and the Facts , 2013, Mediators of inflammation.

[8]  B. Tannous,et al.  Secreted blood reporters: insights and applications. , 2011, Biotechnology advances.

[9]  J. Taubenberger,et al.  The ability of pandemic influenza virus hemagglutinins to induce lower respiratory pathology is associated with decreased surfactant protein D binding. , 2011, Virology.

[10]  F. Magkos,et al.  Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones. , 2011, The Journal of clinical endocrinology and metabolism.

[11]  T. Hankemeier,et al.  RPLC-ion-trap-FTMS method for lipid profiling of plasma: method validation and application to p53 mutant mouse model. , 2008, Journal of proteome research.

[12]  B. Walker,et al.  Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. , 2008, The Journal of endocrinology.

[13]  M. Boers,et al.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases , 2007, Annals of the rheumatic diseases.

[14]  J. Chun,et al.  Lysophospholipid receptors: signaling and biology. , 2004, Annual review of biochemistry.

[15]  W J Jusko,et al.  Prednisolone Pharmacokinetics and Pharmacodynamics in Relation to Sex and Race , 2001, Journal of clinical pharmacology.

[16]  G. Zimmerman,et al.  Lysophosphatidylcholine and lyso-PAF display PAF-like activity derived from contaminating phospholipids. , 2001, Journal of lipid research.

[17]  G. Chisolm,et al.  Regulation of cell growth by oxidized LDL. , 2000, Free radical biology & medicine.

[18]  W. Jusko,et al.  Gender‐based effects on methylprednisolone pharmacokinetics and pharmacodynamics , 1993, Clinical pharmacology and therapeutics.

[19]  D. Mattison,et al.  Sex Differences in Pharmacokinetics and Pharmacodynamics , 2009, Clinical pharmacokinetics.

[20]  M. Lazdunski,et al.  Hydrolysis of minor glycerophospholipids of plasma lipoproteins by human group IIA, V and X secretory phospholipases A2. , 2007, Biochimica et biophysica acta.

[21]  A. Lumsden,et al.  Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. , 2006, Medical science monitor : international medical journal of experimental and clinical research.